Clinical Trial

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial studies how well venetoclax and ibrutinib work in treating participants with chronic lymphocytic leukemia and have developed genetic mutations after previously being treated with ibrutinib. Venetoclax and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2018-04-30; most recent amendment 2026-02-04.
Status change: Recruiting → Active, Not Recruiting 2022-04-08
Status change: Not Yet Recruiting → Recruiting 2019-03-26
Trial Details
NCT Number NCT03513562
Lead Sponsor Ohio State University Comprehensive Cancer Center
Conditions Chronic Lymphocytic Leukemia, Ibrutinib Resistance
Enrollment 28 participants
Start Date 2019-03-26
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-06